Bioventus (BVS) filed a registration statement Friday for the potential sale of up to $200 million of securities from time to time.
The filing covers the sale of the company's class A common stock, preferred stock, debt securities, warrants and units.
The company said certain selling shareholders may offer up to 35 million class A common shares, and Bioventus won't receive any proceeds from the sale.
Shares of the company fell 1.3% in recent after-hours trading.
Price: 13.04, Change: -0.17, Percent Change: -1.29
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。